We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand

MedXY Editorial Team•Nov 24, 2025•news
fear of cancer recurrencehead and neck cancersurvivorship

Highlights

– In a longitudinal cohort of 403 head and neck cancer (HNC) survivors, supportive care needs (SCNs) in the health-system/information domain declined between 2 and 5 years post-treatment; physical, psychological, sexuality and HNC-specific needs remained stable.

– At 5 years, 33% had at least one moderate-to-high unmet SCN; the most common single-item unmet needs were lack of energy/tiredness (9.2%) and dry mouth/sticky mucus (8.1%).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine ClinicA surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancerSep 3, 2026MDADI Composite Score Thresholds for Efficient Screening of Swallowing Impairment in Head and Neck Cancer PatientsThis study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.Aug 27, 2026Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell CarcinomaNeoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.Aug 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.
Aug 21, 2026
Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression LevelsThe addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.Aug 11, 2026
Patient Perceptions of Telehealth Use in Head and Neck Cancer Surveillance: A Qualitative SynthesisThis review synthesizes evidence on patients’ perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.Aug 2, 2026